(Enlonstobart)Biosimilar Reference Antibody-GS40228 新品

货号：GS40228

Enlonstobart (development code XmAb-23104) is an investigational bispecific antibody being developed for the treatment of solid tumors. It represents a next-generation dual-checkpoint immunotherapy engineered to simultaneously target two different inhibitory pathways on immune cells. By co-engaging these two non-redundant receptors—one a well-established checkpoint and another emerging as a key regulator of T-cell exhaustion—enlonstobart is designed to achieve a more complete and potent reversal of T-cell suppression within the tumor microenvironment compared to single-agent checkpoint blockade.